Drug intelligence / Profile preview

Dexde

Development stage: Unknown
Lead developer: Triman
Modality: Small Molecules
Administration: Oral

Overview

**Dexde** is an oral fixed-dose anti-allergy tablet marketed by Triman in Indonesia. Each tablet contains dexamethasone 0.5 mg, a synthetic glucocorticoid that suppresses inflammatory and immune signaling through glucocorticoid-receptor activation, and dexchlorpheniramine maleate 2 mg, a first-generation histamine H1-receptor antihistamine. It is indicated for corticosteroid-responsive allergic conditions including allergic rhinitis, severe chronic bronchial asthma, allergic dermatitis, allergic ocular inflammation, keratitis, and non-granulomatous iritis. ([triman.co.id](https://triman.co.id/dexde.html))

Brand names: Dexde
Other names: dexamethasone + dexchlorpheniramine

Targets

CXADR (Coxsackievirus and adenovirus receptor)GR (Glucocorticoid receptor)PXR (Pregnane X receptor)

Beyond the preview

Go deeper on Dexde.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Dexde.

Explore the full profile